Artificial Intelligence (AI)Cardiac Implantable Electrical DevicesConduction Disorder of the Heart
Investigational drug(s) / intervention(s)
AI-ECG driven ECG monitoring
AI-ECG driven ECG monitoring: Participants identified as high-risk for CIED implantation by the AI-ECG system will receive a continuous cardiac rhythm monitor for up to 7 days.
Study summary
The goal of this clinical trial is to learn whether an artificial intelligence-enhanced electrocardiogram (AI-ECG) strategy improves timely intervention of patients requiring cardiac implantable electronic devices (CIEDs), compared with standard clinical care.
Eligibility
Sex
ALL
Min age
65 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria:
* At least one 12-lead ECG within 1 year
Exclusion Criteria:
* Diagnosis of sick sinus syndrome
* Diagnosis of high-grade or complete atrioventricular block
* Diagnosis of ventricular tachycardia or ventricular fibrillation
* Post CIED implant
* Heart rate below 40 beats per minute by 12-lead ECG
Primary outcome measure(s)
CIED implantation — Within 180 days after randomization The number of participants who undergo CIED implantation within the study period. The CIEDs include conventional transvenous pacemakers, leadless pacemakers, and implantable cardioverter-defibrillators (encompassing transvenous, subcutaneous, and extravascular systems).
Trial sites (1)
Facility
City
Region
Status
Tri-Service General Hospital
Taipei
Taiwan
Recruiting
More National Defense Medical Center, Taiwan trials in Taiwan
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
